

Serotonin is elevated in COVID-19-associated diarrhoea

We read with great interest the recent publication by Lin *et al*,¹ which reported diarrhoea as the most common GI symptom in patients with COVID-19. Diarrhoea as a symptom of COVID-19 has been commonly observed,^{2,3} but the cause remains unknown.

Diarrhoea occurs from excessive production of serotonin (5-hydroxytryptamine, 5-HT) in the GI tract.⁴ Ninety-five per cent of 5-HT is produced and released from the enterochromaffin cells within the epithelium of the GI tract. 5-HT localised to the GI tract is a key modulator of GI peristalsis.⁵ We hypothesised that plasma 5-HT levels are increased in patients with COVID-19 with diarrhoea.

Table 1 summarises the COVID-19 severity, interleukin 6 (IL-6), IgM/IgG antibodies, fever, GI symptoms, plasma 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), underlying diabetes, body mass index, gender and age measured in 80 patients with COVID-19 (10 patients with diarrhoea) and 18 healthy donors (see online supplemental material). Correlation analysis identified 5-HT, 5-HIAA and IL-6 as the most noticeable features in the COVID-19 cohort with diarrhoea. Patients with COVID-19 had significantly increased plasma 5-HT and 5-HIAA levels compared with healthy donors (figure 1A,D). When patients were categorised by disease severity, 5-HT and 5-HIAA levels increased with higher severity of symptoms (figure 1B,E). Patients with COVID-19 with diarrhoea had substantially higher 5-HT and 5-HIAA levels compared with patients without diarrhoea and the healthy group (table 1 and figure 1C,F). Diarrhoea was present in 10 of 80 cases with COVID-19, and all 10 cases with diarrhoea had elevated 5-HT and 5-HIAA levels (figure 1C,F). The ratio of 5-HIAA to 5-HT was significantly lower in those with critical symptoms (figure 1G) and was substantially lower in those with diarrhoea compared with healthy donors or patients without diarrhoea (figure 1H and table 1). A Spearman's rank correlation matrix showed that 5-HT and 5-HIAA levels were correlated with diarrhoea (0.81 and 0.80; $p=0.0017$ and $p=0.0021$), but the 5-HIAA to 5-HT ratio was negatively correlated (-0.43 ; $p=0.0094$) (figure 1I). Additionally, 5-HT, 5-HIAA, 5-HIAA to

Table 1 Clinical characteristics of patients with COVID-19 with GI symptoms

Variables	Patients with COVID-19 with diarrhoea	Patients with COVID-19 without diarrhoea	Healthy control
Total number of cases, n (% of total cases)	10 (12.5)	70 (87.5)	18
SARS-CoV-2 test	Positive	Positive	–
IgM†	0.40±0.12	0.29±0.12	0.07±0.04*
IgG‡	0.30±0.10	0.34±0.14	0.10±0.09*
Fever	5 (50.0)	28 (54.2)	–
COVID-19 severity, n (%)§			
Asymptomatic	–	7 (10.0)	–
Mild	3 (30.0)	38 (54.3)	–
Severe	5 (50.0)	25 (35.7)	–
Critical	2 (20.0)	–	–
IL-6 (pg/mL/1 µg of protein)	102.7±7.2*	67.4±9.3	4.9±5.1**
GI symptoms			
Nausea	3 (30.0)	3 (4.3)	–
Abdominal pain	2 (20.0)	5 (7.1)	–
Vomiting	–	2 (2.9)	–
GI bleeding	–	1 (1.4)	–
Diarrhoea	10 (100)	–	–
5-HT (pg/mL/1 µg of protein)	127.0±18.2**	17.9±11.4	13.7±16.2
5-HIAA (pg/mL/1 µg of protein)	93.1±8.8**	20.3±9.6	8.1±5.1
5-HIAA:5-HT ratio	0.73±0.1*	1.2±0.2	1.3±0.3
Underlying disease			
Diabetes	3 (30.0)	26 (38.2)	–
BMI (kg/m ²)	36.3±8.7	34.1±10.9	22.4±3.1
Gender			
Male	4 (40.0)	40 (60.0)	10 (55.5)
Female	6 (60.0)	30 (40.0)	8 (45.5)
Age (male)			
<40 years	2 (50.0)	6 (15.0)	2 (20.0)
40–60 years	–	15 (37.5)	3 (30.0)
>60 years	2 (50.0)	19 (47.5)	5 (50.0)
Age (female)			
<40 years	–	5 (16.7)	1 (12.5)
40–60 years	1 (16.7)	10 (33.3)	1 (12.5)
>60 years	5 (83.3)	15 (50.0)	6 (75.0)

*P<0.05 and **P<0.01, vs the group of patients with COVID-19 without diarrhoea.

†Healthy control plasma samples were collected before the COVID-19 pandemic.




‡The negative control is less than 0.25.

§The classification of COVID-19 severity was based on WHO guidelines.

BMI, body mass index; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine.

were substantially higher in patients with diarrhoea (102.7; p=0.0384) compared with patients without diarrhoea (67.4) or healthy donors (4.9; p=0.0003) (table 1).

In summary, we found 5-HT levels are markedly elevated in COVID-19-associated diarrhoea. Elevated 5-HT levels in diarrhoea are also correlated with increased IL-6. These data suggest increased 5-HT may contribute to diarrhoea and the severity of COVID-19.

Seeun Ha ,¹ Byungchang Jin,¹ Brooke Clemmensen,¹ Paul Park,¹ Sumaiya Mahboob,² Vadim Gladwill,² Farah Madhani Lovely,³ Andres Gottfried-Blackmore ,⁴ Aida Habtezion ,⁴ Subhash Verma,⁵ Seungil Ro ¹

¹Physiology and Cell Biology, University of Nevada School of Medicine, Reno, Nevada, USA

²Internal Medicine, University of Nevada School of Medicine, Reno, Nevada, USA

³Pulmonary and Critical Care Medicine, Renown Health, Reno, Nevada, USA

⁴Gastroenterology and Hepatology, Stanford University Department of Medicine, Stanford, California, USA

⁵Microbiology and Immunology, University of Nevada School of Medicine, Reno, Nevada, USA

Correspondence to Dr Seungil Ro, Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV 89557-0046, USA; sro@unr.edu

Contributors SH, BJ and SR designed the research. SH, BJ and SR analysed and generated the data. PP, SM, VG, FML, AG-B and AH obtained and analysed COVID-19 and healthy donor blood samples and clinical data. SH, BJ, BC and SR wrote the paper. SR revised the paper. All authors have approved the final version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2020-323542>).

SH and BJ contributed equally.



5-HT ratio and diarrhoea were also highly correlated with IL-6 (0.51, 0.47, –0.48, 0.47; p=0.0078, p=0.0092, p=0.0087, p=0.0089, respectively) and symptom severity (0.58; p=0.0065) (figure 11).

5-HT synthesised and released from the enterochromaffin cells is an important GI signalling molecule that regulates GI motility and inflammation.⁵ Released 5-HT is taken up by enterocytes in the gut and platelets in the blood via the serotonin reuptake transporter and metabolised by the liver and kidney to its metabolite 5-HIAA, which is eventually excreted to urine.⁶ 5-HT and 5-HIAA levels are stable in plasma, serving as useful markers to study patients with IBS.⁷ Increased 5-HT in the gut leads to diarrhoea in patients with IBS-D.⁸ GI

symptom studies in patients with COVID-19 have shown diarrhoea is common.⁹ In the present study, we found elevated 5-HT and 5-HIAA levels in patients with COVID-19 are correlated with diarrhoea. Interestingly, the diarrhoea group (0.73; p=0.0409) had a significantly lower ratio of 5-HIAA to 5-HT than the non-diarrhoea (1.2) and healthy donor (1.3; p=0.1105) groups (table 1). This finding suggests 5-HT in the diarrhoea group remains elevated due to delayed or insufficient breakdown to 5-HIAA. In addition, our data indicate 5-HT and 5-HIAA levels are positively correlated with a proinflammatory cytokine IL-6, which is an essential pathogenic cytokine for COVID-19 severity.¹⁰ IL-6 levels




Figure 1 Profiles of plasma 5-HT and 5-HIAA in patients with COVID-19 with different severity and diarrhoea. (A–C) Plasma levels of 5-HT in a group of healthy individuals (n=18) and patients with COVID-19 (n=80) (A), in a group of healthy individuals and patients with COVID-19 with asymptomatic, mild, severe and critical conditions (B), and in a group of healthy individuals and patients with COVID-19 with and without diarrhoea (with diarrhoea n=10, without diarrhoea n=70) (C). (D–F) Plasma levels of 5-HIAA in a group of healthy individuals (n=18) and patients with COVID-19 (n=80) (D), in a group of healthy individuals and patients with COVID-19 with asymptomatic, mild, severe and critical conditions (E), and in a group of healthy individuals and patients with COVID-19 with and without diarrhoea (F). (G and H) Comparison of plasma 5-HIAA to 5-HT ratio in patients with COVID-19 with different severity and in a group of healthy individuals (G) and patients with COVID-19 with and without diarrhoea (H). (I) Correlation matrix of severity, fever, IL-6, 5-HT, 5-HIAA and GI symptoms in patients with COVID-19. Correlation matrix shows the Spearman's rank correlation among severity (asymptomatic, 1; mild, 2; severe, 3; critical, 4), fever, IL-6, 5-HT and GI symptoms (diarrhoea, abdominal pain, nausea, vomiting and GI bleeding) in patients with COVID-19 (n=80). A correlation number of 1.0 or –1.0 indicates 100% of patients with a positive (blue) or negative (red) correlation. Statistical analysis was performed with two-way analysis of variance. P<0.05 was considered significant (*p<0.05, **p<0.01). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; IL-6, interleukin 6.

To cite Ha S, Jin B, Clemmensen B, *et al.* *Gut* 2021;70:2015–2017.

Gut 2021;70:2015–2017. doi:10.1136/gutjnl-2020-323542

Received 3 November 2020
 Revised 17 December 2020
 Accepted 23 December 2020
 Published Online First 5 January 2021

ORCID iDs
 Seun Ha <http://orcid.org/0000-0001-6063-5559>
 Andres Gottfried-Blackmore <http://orcid.org/0000-0002-3563-3727>
 Aida Habtezion <http://orcid.org/0000-0002-4473-006X>

REFERENCES

- Lin L, Jiang X, Zhang Z, *et al.* Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. *Gut* 2020;69:997–1001.
- Wang D, Hu B, Hu C, *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–Infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–9.
- Buscarini E, Manfredi G, Brambilla G, *et al.* Gi symptoms as early signs of COVID-19 in hospitalised Italian patients. *Gut* 2020;69:1547–8.
- Barbara G, Feinle-Bisset C, Ghoshal UC, *et al.* The intestinal microenvironment and functional gastrointestinal disorders. *Gastroenterology* 2016;150:1305–18.
- Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. *Gastroenterology* 2007;132:397–414.
- Wan M, Ding L, Wang D, *et al.* Serotonin: a potent immune cell modulator in autoimmune diseases. *Front Immunol* 2020;11:186.
- Atkinson W, Lockhart S, Whorwell PJ, *et al.* Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. *Gastroenterology* 2006;130:34–43.
- Black CJ, Burr NE, Camilleri M, *et al.* Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. *Gut* 2020;69:74–82.
- Galanopoulos M, Gkeros F, Doukatas A, Karianakis G, *et al.* COVID-19 pandemic: pathophysiology and manifestations from the gastrointestinal tract. *WJG* 2020;26:4579–88.
- Del Valle DM, Kim-Schulze S, Huang H-H, *et al.* An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020;26:1636–43.